ABVC BioPharma, Inc. (ABVC )

Currency in USD Disclaimer
$0.59 +$0.08 (16.42%)
Closed 10/15/2024
$0.52
$0.71
$0.41
$3.35

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol ABVC
  • Company ABVC BioPharma, Inc.
  • Price $0.59
  • Changes Percentage 16.42
  • Change 0.0828
  • Day Low $0.52
  • Day High $0.71
  • Year High $3.35
  • Year Low $0.41
  • Market Cap $7,292,839
  • Price Avg 50 EMA (D) $0.66
  • Price Avg 200 EMA (D) $0.99
  • Exchange NASDAQ
  • Volume 1,922,371
  • Average Volume 79,759
  • Open $0.53
  • Previous Close $0.5
  • EPS -1.66
  • PE -0.35
  • Earnings Announcement 2024-11-13 00:00:00
  • Shares Outstanding $12,421,800

Company brief: ABVC BIOPHARMA, INC. (ABVC )

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

ABVC Corporation News

Income Statement